Browse the evidence

AgRP neuron hyperactivity contributes to chronic insulin resistance and obesity by inducing brown adipose tissue-derived myostatin expression, which systemically inhibits insulin signaling in skeletal muscle and white adipose tissue.

This mechanism explains why some individuals with obesity struggle with insulin resistance beyond just fat mass. It suggests that targeting the AgRP-myostatin pathway could be a therapeutic strategy, although current treatments focus more broadly on GLP-1 and MC4R pathways.

Integrating structured intake tools (like the Obesity Brief HPI) into electronic medical records can increase the identification and prioritization of weight management visits, although adoption was zero in this baseline period.

Health systems are starting to use digital tools to make weight management easier. If your clinic uses these tools, expect a questionnaire before your visit. This is designed to help your doctor understand your history better, not to burden you.

Tirzepatide reduces MC38 colon tumor growth rates in diet-induced obese mice by approximately 50%, but this effect is indirect and mediated by reduced food intake, lower insulin, and lower leptin levels rather than direct anti-proliferative action on cancer cells.

For obese individuals with early-stage, insulin-sensitive cancers (like colon cancer), tirzepatide may help slow tumor growth. This benefit appears to come from reducing insulin and leptin levels through weight loss and appetite suppression, not from directly attacking the cancer cells. It is not a cure, but it may improve outcomes by altering the metabolic environment that fuels cancer growth.

Ingestion of an isonitrogenous non-essential amino acid (NEAA) formulation does not stimulate muscle protein synthesis (MPS) or activate mTOR signaling pathways in skeletal muscle cells, making it an effective non-bioactive control for protein bioactivity studies.

If you are looking to stimulate muscle growth, consuming non-essential amino acids (NEAA) alone will not trigger the necessary biological signals. Muscle protein synthesis is driven by essential amino acids (EAAs), specifically leucine. Use NEAA as a control or filler in studies, but rely on complete proteins or EAAs for actual muscle building effects.

Physical activity time and variability are not significantly associated with glycemic variability indices (MAGE, CONGA, MODD) in overweight or obese adults.

Do not rely on exercise alone to stop blood sugar spikes or swings if you are overweight. While exercise helps lower your average blood sugar, this study suggests it may not reduce the magnitude of glucose fluctuations. Focus on total movement time rather than expecting it to smooth out glucose curves.

In patients with advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD), higher BMI is paradoxically associated with lower mortality rates, likely due to nutritional reserves and muscle mass.

If you have advanced kidney disease, being overweight might actually protect you from early death by providing essential energy and muscle reserves. Discuss weight management goals with your nephrologist, as the strategy may differ from general population advice.

A two-meals-a-day ketogenic diet may cause an increase in serum uric acid levels in patients with type 2 diabetes.

Monitor uric acid levels when starting this diet, as it may rise. This is a known trade-off of ketosis.

There is no significant association between competitor characteristics (age, sex, drug status, level) and the use of carbohydrate-based peaking strategies or the length of the peaking strategy.

Do not assume your carbohydrate strategy must change based on your sex, age, or drug status. The study found no link between these factors and CHO strategy choice. However, be aware that the *range* of carbohydrate intake (high vs low days) during peak week is significantly influenced by sex.

Sex is a significant predictor of the disparity (range) between highest and lowest daily carbohydrate intakes during peak week, with males exhibiting a wider range than females.

If you are male, expect to cycle your carbohydrates more aggressively (higher highs and lower lows) during peak week than if you are female. The study found sex was the only significant factor predicting this disparity.

Bariatric surgery may not provide long-term reductions in depressive symptoms for patients with obesity and depression, despite improving quality of life.

Bariatric surgery is effective for weight loss but may not resolve depression long-term. Ensure you have a mental health support plan before and after surgery.

Semaglutide 2.4 mg use is associated with significant side effects, including gastrointestinal distress and rare but severe complications like pancreatitis.

Be prepared for gastrointestinal side effects, especially when starting or increasing the dose. These often subside, but severe symptoms like pancreatitis require immediate medical attention.

Access to semaglutide 2.4 mg is significantly hindered by national shortages, high costs, and insurance coverage issues.

Secure insurance coverage early. Be aware of potential shortages and costs. Utilize patient assistance programs if out-of-pocket costs are prohibitive.

GLP-1RAs may pose theoretical risks for individuals with restrictive eating disorders (e.g., Anorexia Nervosa) or high perfectionism, as appetite suppression can mask or reinforce rigid control and compensatory behaviors.

If you have a history of restrictive eating disorders or high perfectionism, GLP-1RAs require careful monitoring. The medication's ability to suppress appetite might mask or worsen restrictive behaviors, so prescribers should screen for these risks and watch for red flags like rapid weight loss or dizziness.

Discontinuation of incretin therapy leads to weight regain that is proportional in composition (fat and lean mass) to the initial loss, challenging the belief that regained weight is predominantly fat.

If you stop your GLP-1 medication, you will likely regain weight. Contrary to popular belief, this regained weight is not just fat; it includes muscle and other lean tissue, following a similar ratio to what you lost. However, older adults may struggle to regenerate muscle, so maintaining activity is crucial.

Baseline gut microbiome composition predicts the efficacy of semaglutide and empagliflozin in reducing HbA1c, whereas the drugs themselves do not significantly alter microbial diversity or composition.

If you are starting semaglutide or empagliflozin for Type 2 Diabetes, your current gut bacteria might predict how much your blood sugar (HbA1c) will drop. The drugs themselves don't seem to drastically change your gut diversity, but knowing your baseline microbiome could help personalize your treatment. This is still early research, so discuss testing options with your doctor.

Pharmacotherapy may reduce bariatric surgical volume, particularly among patients with BMI 30-40, by providing a less invasive alternative.

If you have a BMI between 30 and 40, you now have a highly effective non-surgical option that may prevent the need for surgery. This is changing how doctors treat obesity.

Phentermine is generally avoided in older adults due to risks of falls, anxiety exacerbation, and cardiovascular side effects, despite its efficacy in younger populations.

Phentermine is rarely recommended for older adults because it can cause dizziness (increasing fall risk), worsen anxiety, and strain the heart. It is generally avoided in this age group due to multiple comorbidities.

GLP-1 agonist pharmacotherapy for obesity in women may not be economically justified by healthcare cost savings alone, as the high lifetime cost of obesity is largely driven by reduced life expectancy rather than increased annual healthcare utilization.

For women with obesity, using GLP-1 medications like semaglutide or tirzepatide is a significant financial investment. Current economic models suggest that simply saving on annual medical bills for obesity-related conditions may not cover the drug costs. However, if the treatment successfully extends life expectancy by even 50% of the years lost to obesity, the long-term value to the healthcare system and the patient's quality of life can justify the expense.

DJB implantation leads to significant improvements in liver enzymes (AST, ALT, GGT) and lipid panels (LDL, Cholesterol, HDL, TAG).

DJB implantation improves liver health (reducing enzymes like AST and ALT) and improves lipid profiles (lowering bad cholesterol and triglycerides, raising good cholesterol).

Nanomedicine delivery systems can enhance the efficacy of glucose-lowering drugs by enabling site-specific delivery to macrophages, potentially inducing plaque regression.

This is currently a research area. While standard GLP-1 injections work, scientists are developing nanoparticle versions that might target heart plaques directly. This is not yet available for routine clinical use.

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe caloric restriction, dehydration, and acute kidney injury, particularly in unmonitored or high-risk populations.

If you are prescribed a GLP-1 agonist (like Ozempic or Mounjaro), do not use it without medical supervision. Ensure you are screened for eating disorders and receive dietary counseling. Watch for signs of extreme food aversion or dehydration, and stop the medication if you lose weight too rapidly or feel severe nausea/diarrhea, seeking immediate medical attention if you experience kidney issues.

GLP-1 receptor agonists can trigger or exacerbate restrictive eating behaviors and food aversions, mimicking Avoidant/Restrictive Food Intake Disorder (ARFID), in patients with obesity and those with rare genetic disorders of obesity.

Be aware that GLP-1s can make you lose interest in food entirely. If you find yourself unable to eat enough to maintain your health, or if you develop strong aversions to specific foods, inform your doctor immediately. This may require dose reduction or discontinuation.

Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.

If you start Tirzepatide, expect gastrointestinal issues like nausea or diarrhea, especially in the first month. These are common reasons for stopping treatment. Starting at the lowest dose (5mg) might help you tolerate the medication better, as higher doses are linked to later but potentially more severe onset of side effects. Monitor your symptoms closely during the first few weeks.

Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.

If you are over 65 and start Tirzepatide, be extra vigilant in the first two weeks. Side effects like nausea or dizziness may hit you much sooner than they would for a younger person. Report any severe symptoms to your doctor immediately, as discontinuation rates are higher in this age group.